Study examines risk of bleeding among patients taking 2 anti-platelet drugs

November 22, 2010

Dual antiplatelet therapy--treatment with the medications clopidogrel and aspirin together to prevent blood clots--poses a clinically significant risk of hemorrhage that should be considered before prescribing, according to a report in the November 22 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

Dual antiplatelet therapy with clopidogrel plus aspirin is commonly used to prevent blood clots in patients with cardiovascular disease, according to background information in the article. The treatment has demonstrated a benefit in reducing the formation of clots in stents and also in preventing blocked blood vessels in patients who have had a heart attack or other form of acute coronary syndrome. Although warfarin remains the standard of care for treatment of a wide variety of clot-related conditions, the strategy of dual antiplatelet therapy has gained increased attention as an alternative for some patients.

Nadine Shehab, Pharm.D., M.P.H., of the Centers for Disease Control and Prevention, Atlanta, and colleagues used national databases to identify emergency department visits for hemorrhage-related adverse events from either dual antiplatelet therapy or warfarin between 2006 and 2008.

The researchers identified 384 annual emergency department visits for hemorrhage-related adverse events among patients taking dual antiplatelet therapy and 2,926 annual visits for those taking warfarin. Approximately 60 percent of emergency department visits for dual antiplatelet therapy consisted of epistaxis (nosebleeds) or minor hemorrhages. The estimated rate of emergency department visits was 1.2 per 1,000 outpatient prescription visits among patients taking dual antiplatelet therapy compared with 2.5 per 1,000 outpatient prescription visits taking warfarin.

"Although we found the overall risk of hemorrhage-related emergency department visits to be three-fold higher for warfarin than for clopidogrel plus aspirin, a little more than one-half of the emergency department visits for acute hemorrhages due to warfarin were composed of minor hemorrhages and one-quarter of warfarin-related emergency department visits, overall, were for elevation of laboratory coagulation variables without documentation of hemorrhage," the authors write. When only documented hemorrhages were considered, the risk of an emergency department visit was only doubled (rather than tripled) among warfarin users compared with those taking clopidogrel plus aspirin.

"The beneficial role of dual antiplatelet therapy is well established in patients with acute coronary syndromes and may potentially expand to a subset of patients with atrial fibrillation," the authors conclude. "Ultimately, for each patient, the hemorrhagic risk associated with dual antiplatelet therapy will be determined by his or her specific demographic and clinical risk factors, underlying diagnosis, treatment setting and quality of clinical care. Broadly, however, these nationally representative findings on adverse events indicate that the hemorrhagic risk of clopidogrel plus aspirin therapy is substantial and suggest a need to approach that risk with vigilance."
-end-
(Arch Intern Med. 2010;170[21]:1926-1933. Available pre-embargo to the media at www.jamamedia.org.)

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

To contact Nadine Shehab, Pharm.D., M.P.H., call Kristen Nordlund at 404-639-3286 or e-mail hok4@cdc.gov.

For more information, contact JAMA/Archives Media Relations at 312/464-JAMA (5262) or e-mail mediarelations@jama-archives.org.

The JAMA Network Journals

Related Aspirin Articles from Brightsurf:

An aspirin a day keeps the bowel doctor away
A regular dose of aspirin to reduce the risk of inherited bowel cancer lasts at least 10 years after stopping treatment, research has revealed.

What are the risks and benefits of low-dose aspirin?
Low-dose aspirin significantly lowers cardiovascular disease risk but increases the risk of bleeding, according to a review published in the British Journal of Clinical Pharmacology.

Benefit seen for ticagrelor alone, without aspirin, in patients with ACS
The research was presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

Study: An aspirin a day does not keep dementia at bay
Taking a low-dose aspirin once a day does not reduce the risk of thinking and memory problems caused by mild cognitive impairment or probable Alzheimer's disease, nor does it slow the rate of cognitive decline, according to a large study published in the March 25, 2020, online issue of Neurology®, the medical journal of the American Academy of Neurology.

Aspirin's health benefits under scrutiny
Taking a baby aspirin every day to prevent a heart attack or stroke should no longer be recommended to patients who haven't already experienced one of these events.

Aspirin may no longer be effective as cardiovascular treatment
A new paper in Family Practice, published by Oxford University Press, found that the widespread use of statins and cancer screening technology may have altered the benefits of aspirin use.

Migraine headaches? Consider aspirin for treatment and prevention
Evidence from 13 randomized trials of the treatment of migraine in 4,222 patients and tens of thousands of patients in prevention of recurrent attacks supports the use of high dose aspirin from 900 to 1,300 milligrams to treat acute migraine as well as low dose daily aspirin from 81 to 325 milligrams to prevent recurrent attacks.

Aspirin use after biliary tract cancer diagnosis
Researchers in this observational study examined if aspirin use after a diagnosis of a biliary tract cancer, which includes gallbladder cancer, was associated with reduced risk of death among nearly 3,000 patients.

Aspirin may prevent air pollution harms
A new study is the first to report evidence that nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin may lessen the adverse effects of air pollution exposure on lung function.

Aspirin should not be recommended for healthy people over 70
Low-dose aspirin does not prolong disability-free survival of healthy people over 70, even in those at the highest risk of cardiovascular disease.

Read More: Aspirin News and Aspirin Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.